At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025, the deal ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation ...

China’s WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to US drug maker Merck & Co for about US$500 million, ahead of potential US legislation that would restrict ...

Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

Pharmaceutical firm MSD has agreed a deal to buy the WuXi Vaccines manufacturing facility in Dundalk, Co Louth as part of its long-term plans in Ireland. MSD said the deal is worth €500m and ...

The head of MSD’s manufacturing division, Sanat Chattopadhyay, said MSD’s manufacturing footprint in Ireland was unparalleled. He said the acquisition of the Wuxi site would help his company ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million. The Financial Times had reported in October, citing people familiar with the matter, ...